# Effect of DPP4 Inhibition on Vasoconstriction

> **NCT02639637** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 18 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo
- **DRUG:** Neuropeptide Y
- **DRUG:** Enalaprilat
- **DRUG:** Valsartan 160mg

## Key facts

- **NCT ID:** NCT02639637
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-06
- **Final completion:** 2017-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639637, "Effect of DPP4 Inhibition on Vasoconstriction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02639637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*